Cellenkos, Inc.

We’re proud to share results from our clinical study published in NEJM Evidence and now featured in our press release. Our off-the-shelf, cord blood-derived Treg cell therapy showed: -Clinical safety across multiple infusions -Signs of slowed ALS disease progression -No need for HLA matching or lymphodepletion -Outpatient administration and a favorable safety profile “These results are both encouraging and transformative for those battling ALS. Our Treg therapy is cryopreserved, ready-to-use, outpatient-based, and eliminates the need for HLA matching or preconditioning.” — Dr. Simrit Parmar, Founder, Cellenkos This milestone brings us closer to accessible, immune-modulating therapies for neurodegenerative diseases. https://lnkd.in/ghqhCNZG #ALS #TregTherapy #CellTherapy #NEJMEvidence #ClinicalTrials #Neurodegeneration #Biotech #ALSTreatment #HealthcareInnovation #CBA

🚀 The Incredible Journey of our founder, Dr. Simrit Parmar in Cellular Therapy! 🎙️ Join Chadi Nabhan, MD, MBA,FACP on Healthcare Unfiltered as he sits down with the inspiring Dr. Parmar (@LurieCancer alum) to dive into her start-up journey—from the initial idea to the challenges of breaking into the cellular therapy space. 💡 How did it all begin? ⚡ What were the toughest hurdles? 🎯 What does the future hold? This episode is so good—you’ll want to listen twice! 🔥 🎧 Listen now: Apple Podcasts #HealthcareUnfiltered #Biotech #Startups #CellTherapy https://lnkd.in/eKXj-RfG Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous process of demonstrating safety and efficacy to the FDA. Additionally, she provides a glimpse into the company’s pipeline of innovative cellular therapies aimed at addressing unmet medical needs. Find out more about Cellenkos. https://lnkd.in/eZaZwwjQ Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. https://lnkd.in/eyiwwZNy

Catch Tara Sadeghi, #Cellenkos Chief Operating Officer, on March 18, 2025 at 1550 PM at the #AdvancedTherapiesCongress2025, London. Talking about "From Bench to Bedside: Challenges and Solutions in Cell Therapy Translation"

How is Cellenkos advancing umbilical cord blood-derived Treg therapies? Join #CellAndGenePodcast’s Erin Harris Harris & Cellenkos Founder Dr. Simrit Parmar as they discuss breakthroughs in autoimmune disease treatments, CRANE tech, and what’s next for 2025!   “These are truly off the shelf therapies that can be cryopreserved, stored for years, can be administered in the doctor's office, in the outpatient setting, through a peripheral IV line, and more importantly, Cellenkos’ Treg cells can seek out the diseased areas, resolve the inflammatory processes, and restore homeostasis and normalcy.” Listen in as Dr. Simrit Parmar joins #CellAndGenePodcast. Erin Harris #Tregs #autoimmune ds.

We're excited to welcome Dr Jonathan Weis as the Head of Business Development of Cellenkos Inc.

We are excited to share feature on Cellenkos' CRANE technology that harnesses regulatory T cells to precisely target and treat inflammatory diseases in Drug Target Review. https://lnkd.in/eAuNyD9h

As we close #RareDiseaseMonth, we are grateful for organizations like the Aplastic Anemia & MDS International Foundation for their work in empowering patients with #AplasticAnemia by providing helpful resources and information to better understand their disease and guide them on their journeys. Learn more about ongoing research and efforts to combat aplastic anemia by visiting their site: https://bit.ly/3Q6hbQ3 #RareDiseaseDay

Catch our founder, Simrit Parmar, in conversation with Karen Jagoda on the latest episode of The Empowered Patient podcast. She shared insights into her #biotech journey and why she believes that off the shelf, allogenic #Treg cell therapies have significant potential to restore immune balance in patients facing autoimmune and inflammatory diseases.

Did you know? #AplasticAnemia is a serious #RareDisease where the bone marrow does not produce enough blood cells. Patients living with aplastic anemia experience burdensome symptoms, may require frequent blood transfusions and face a diminished quality of life. Learn more about this condition: https://bit.ly/42WjYme.